title: [Experiences in treatment and follow up of 50 patients with penile cancer].
abstract: BACKGROUND
  Malignant tumour of the penis is a rare disease. Although most of the cases are squamous cell carcinoma histologically, operation is managed by the urologist because of its location.
  
  
  OBJECTIVE
  Experience with the treatment and attendance of penile cancer is presented by the author. Results were both retrospectively and prospectively worked up.
  
  
  RESULTS
  Between June 1996 and June 2006 there was operation performed in 50 patients. Mean age of men was 63.1 (31-83) years. Ninety-four percent of tumours were squamous cell carcinoma, 2 (4%) verrucosus carcinoma, in one case malignant melanoma. Pathological T stadium was T1 in 23 cases (46%), T2 in 19 (38%) patients, in 6 (12%) cases T3 and in 1 (2%) T4. Differentiation was grade 1 in 12 (24%), grade 2 in 27 (54%) and grade 3 in 10 (20%) cases. One side inguinal lymph node metastases were found in 11 (22%) and both side in 8 (16%) patients. In anamnesis 4 (8%) patients underwent circumcision because of phimosis, and 25 (50%) patients had had phimosis by identification of cancer. Seventeen patients (34%) were given chemotherapy after surgical treatment. Mean survival time of all patients was 31,4 (2-114) months.
  
  
  CONCLUSIONS
  Phimosis plays an important role in development of penile cancer, that's surgical treatment does not prevent the higher chance of incidence rate. The disease behaves aggressively, spreading through lymphatic vessels, where in advanced stadium, or in low differentiation cases it is already demonstrable by diagnosis. In the choice of therapy, stadium-oriented principle should be predominant. With early operation, long-term survival can be achieved.
authors.affiliation: Semmelweis Egyetem, Altalános Orvostudományi Kar, Urológiai Klinika, Budapest. riessp@freemail.hu
authors.forename: Péter
authors.initials: P
authors.lastname: Riesz
authors.forename: Péter
authors.initials: P
authors.lastname: Nyirády
authors.forename: Miklós
authors.initials: M
authors.lastname: Szucs
authors.forename: Attila
authors.initials: A
authors.lastname: Szendrôi
authors.forename: Attila
authors.initials: A
authors.lastname: Majoros
authors.forename: Gergely
authors.initials: G
authors.lastname: Bánfi
authors.forename: András
authors.initials: A
authors.lastname: Kiss
authors.forename: Gábor
authors.initials: G
authors.lastname: Lotz
authors.forename: Péter
authors.initials: P
authors.lastname: Törzsök
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Kelemen
authors.forename: Imre
authors.initials: I
authors.lastname: Romics
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D018289:Carcinoma, Verrucous / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000628:therapy; D008875:Middle Aged; D009367:Neoplasm Staging; D010412:Penile Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome